WS #15605
Guggenheim reiterated a Buy rating on AbbVie with a $288 price target, citing strong pipeline fundamentals. Teva Pharmaceuticals won FDA approval for its monthly schizophrenia injection, Weltruza, which could significantly expand its market share in the CNS drug category. These developments provide defensive pockets of growth in the healthcare sector amidst broader market volatility.
Pharma & Biotech Movers
Guggenheim reiterated a Buy rating on AbbVie with a $288 price target, citing strong pipeline fundamentals. Teva Pharmaceuticals won FDA approval for its monthly schizophrenia injection, Weltruza, which could significantly expand its market share in the CNS drug category. These developments provide defensive pockets of growth in the healthcare sector amidst broader market volatility.